

The subcommittee meetings will be closed to the public in accordance with the Federal Advisory Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C. 552b(c)(6). Grant applications are to be reviewed and discussed at these meetings. These discussions are likely to involve information concerning individuals associated with the applications, including assessments of their personal qualifications to conduct their proposed projects. This information is exempt from mandatory disclosure under the above-cited statutes.

1. *Name of Subcommittee:* Healthcare Effectiveness and Outcomes Research.

*Date:* June 19, 2012 (Open from 8:00 a.m. to 8:15 a.m. on June 19 and closed for remainder of the meeting).

*Place:* Crowne Plaza Rockville, 3 Research Court, Rockville, MD 20850.

2. *Name of Subcommittee:* Health Safety and Quality Improvement Research.

*Date:* June 19–20, 2012 (Open from 8:00 a.m. to 8:15 a.m. on June 19 and closed for remainder of the meeting).

*Place:* Crowne Plaza Rockville, 3 Research Court, Rockville, MD 20850.

3. *Name of Subcommittee:* Health Systems and Value Research.

*Date:* June 20, 2012 (Open from 8:00 a.m. to 8:15 a.m. on June 20 and closed for remainder of the meeting).

*Place:* Crowne Plain Rockville, 3 Research Court, Rockville, MD 20850.

4. *Name of Subcommittee:* Health Care Research Training.

*Date:* June 21–22, 2012 (Open from 8:30 a.m. to 8:45 a.m. on June 21 and closed for remainder of the meeting).

*Place:* Crowne Plaza Rockville, 3 Research Court, Rockville, MD 20850.

5. *Name of Subcommittee:* Healthcare Information Technology Research.

*Date:* June 28–29, 2012 (Open from 8:00 a.m. to 8:15 a.m. on June 28 and closed for remainder of the meeting).

*Place:* Crowne Plaza Rockville, 3 Research Court, Rockville, MD 20850.

*Contact Person:* Anyone wishing to obtain a roster of members, agenda or minutes of the nonconfidential portions of the meetings should contact Mrs. Bonnie Campbell, Committee Management Officer, Office of Extramural Research, Education and Priority Populations, AHRQ, 540 Gaither Road, Suite 2000, Rockville, Maryland 20850, Telephone (301) 427–1554.

Agenda items for these meetings are subject to change as priorities dictate.

Dated: May 31, 2012.

**Carolyn M. Clancy,**

*Director.*

[FR Doc. 2012–13772 Filed 6–14–12; 11:15 am]

**BILLING CODE 4160–90–M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Submission for OMB Review; Comment Request

*Title:* Impact Studies of the Health Professions Opportunity Grants.

*OMB No.:* 0970–0394.

The Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS) is proposing data collection activities as part of the Impact Studies of the Health Professions Opportunity Grants (HPOG–Impact). The goal of HPOG–Impact is to evaluate the effectiveness of approaches HPOG grantees use to provide Temporary Assistance for Needy Families (TANF) recipients and other low-income individuals with opportunities for education, training and advancement within the health care field. HPOG–Impact also is intended to evaluate variation in participant impact that may be attributable to different HPOG program components and models. The impact study design is a classic experiment in which eligible applicants for HPOG program services will be randomly assigned to a treatment group offered participation in HPOG and a control group not offered the opportunity to enroll in HPOG.

To achieve these goals, it is necessary to collect data about both treatment group and control group sample members before enrollment into the HPOG program. The information collection proposed will supplement internet-based collection of information from HPOG grantees on baseline characteristics of eligible program participants. This 30-day notice describes the universe of data collection efforts for this study. However, this information collection request is limited to the Supplemental Baseline Questions (for program participants and control group members) described under 1 below. As part of this submission, we are also requesting permission to waive 60-day notices necessary for future and follow-up surveys (described under 2–6 below).

The universe of information collection proposed for HPOG–Impact includes:

1. Supplemental Baseline Questions (for program participants and control

group members). This survey will augment data already collected about eligible program applicants through the Performance Reporting System (PRS) that currently is being used in the Implementation, Systems and Outcome Evaluation of the TANF and Low-Income Health Profession Opportunity Grants (OMB Control No. 0970–0394). To reduce burden to the extent possible, HPOG–Impact will use data from the PRS. The 15-minute “supplemental survey” will collect any additional information necessary for HPOG–Impact and will be administered prior to random assignment.

2. 12-Month Follow-up Survey. This survey will be administered approximately 12 months after baseline to both treatment and control group members. It will collect data about program experiences and outcomes of interest, including certifications and educational achievements, job placement, wages, and benefits. It also will collect some information about participants’ tenure and experience in HPOG programming.

3. Grantee Survey. This survey will be administered to all HPOG grantees participating in HPOG–Impact, will collect information on characteristics of HPOG programs and will be used to classify grantees and to identifying distinct service delivery models.

4. Case studies of selected HPOG grantees. Through site visits, site research staff will also use structured observations and staff and management interviews to validate the results of the Grantee Survey.

5. 30–3-Month Follow-up Survey. This survey will be administered approximately 30 months after baseline to both treatment and control group members. It will collect updated information about outcomes of interest, including certifications and educational achievements, job placement, wages, and benefits.

6. Follow up data collection on children of study participants. Data on child outcomes that may be associated with parental impacts tied to program participation and components will be collected at follow-up. Data collection will vary depending on children’s ages.

*Respondents:* Individuals enrolled in HPOG interventions; control group members.

## ANNUAL BURDEN ESTIMATES

Instrument	Annual number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
HPOG Performance Reporting System (PRS) (previously approved). .....	32	2	31.2	1,997
Supplemental Baseline Questions (program participants and control group members) .....	5,125	1	0.25	1,281
Supplemental Baseline Questions (grantees) .....	32	160	0.25	1,280

*Estimated Total Annual Burden Hours:* 4,558.

**Additional Information:**

Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: OPRE Reports Clearance Officer. All requests should be identified by the title of the information collection. Email address: [OPREinfocollection@acf.hhs.gov](mailto:OPREinfocollection@acf.hhs.gov)

**OMB Comment:**

OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following:

Office of Management and Budget, Paperwork Reduction Project, Email: [OIRA\\_SUBMISSION@OMB.EOP.GOV](mailto:OIRA_SUBMISSION@OMB.EOP.GOV), Attn: Desk Officer for the Administration, for Children and Families.

**Steven M. Hanmer,**

*OPRE Reports Clearance Officer.*

[FR Doc. 2012-14656 Filed 6-15-12; 8:45 am]

**BILLING CODE 4184-09-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2012-N-0011]

#### Academic Development of a Training Program for Good Laboratory Practices in High Containment Environments (U24)

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of a Funding Opportunity

Announcement (FOA) entitled "Academic Development of a Training Program for Good Laboratory Practices in High Containment Environments (U24)." In this FOA, FDA announces its intention to accept and consider a single source application for an award to the University of Texas Medical Branch (UTMB) Galveston National Laboratory (GNL) for the development and implementation of a certified, academic training course for instruction in Good Laboratory Practices (GLP) in a Biosafety Level (BSL) 4 High Containment Environment. FDA seeks to support an effort to design a robust, collaborative, and educational program using problem-based learning techniques designed to bring researchers and regulators together to educate each other on the challenges related to these issues and to identify solutions that are acceptable from both scientific and regulatory perspectives.

**DATES:** Important dates are as follows:

1. The application due date is July 16, 2012.
2. The anticipated start date is September 15, 2012.
3. The opening date is June 18, 2012.
4. The expiration date is July 17, 2012.

**ADDRESSES:** Submit the paper application to: Gladys Melendez Bohler, Office of Acquisitions and Grants Services (HFA-500), 5630 Fishers Lane, rm. 1078, Rockville, MD 20857, 301-827-7175, email: [gladys.bohler@fda.hhs.gov](mailto:gladys.bohler@fda.hhs.gov). For more information, see section III of the **SUPPLEMENTARY INFORMATION** section of this notice.

**FOR FURTHER INFORMATION CONTACT:**

CAPT. Estella Jones, Office of the Chief Scientist, Food and Drug Administration, Bldg. 32, rm. 4130, Silver Spring, MD 20993, 301-796-0742, Email: [estella.jones@fda.hhs.gov](mailto:estella.jones@fda.hhs.gov);  
or  
Lisa Hensley, Office of Counterterrorism and Emerging Threats, Food and Drug Administration, Bldg. 32, rm. 4128, Silver Spring, MD 20993, 301-796-8518, Email:

[lisa.hensley@fda.hhs.gov](mailto:lisa.hensley@fda.hhs.gov); or  
Gladys Melendez Bohler, Office of Acquisitions and Grants Services

(HFA-500), 5630 Fishers Lane, rm. 1078, Rockville, MD 20857, 301-827-7175, Email: [gladys.bohler@fda.hhs.gov](mailto:gladys.bohler@fda.hhs.gov).

For more information on this funding opportunity announcement (FOA) and to obtain detailed requirements, please refer to the full FOA located at <http://www.fda.gov/EmergencyPreparedness/MedicalCountermeasures/default.htm>.

**SUPPLEMENTARY INFORMATION:****I. Funding Opportunity Description**

Request for Application: RFA-FD-12-024  
Catalog of Federal Domestic Assistance: 93.103

**A. Background**

FDA's Office of Counterterrorism and Emerging Threats (OCET) is a leader and active participant in the public health community and with the military defense community, helping to advance the development, evaluation, and approval of medical countermeasures to be used against threats involving chemical, biological, radiological, or nuclear (CBRN) agents. In 2010, FDA launched its Medical Countermeasures initiative (MCMi) in response to a report by the Secretary of the Department of Health and Human Services to assess the our nation's emergency readiness and in answer to a charge by President Obama to improve our nation's capacity to respond faster and more effectively to CBRN and emerging infectious disease threats—such as pandemic influenza. OCET was tasked with leading the implementation of the MCMi. OCET's activities are informed by the knowledge that protecting the civilian public and the warfighter against CBRN agents is a national security priority. A significant area of engagement for OCET is its support of innovative science to advance CBRN countermeasure development with the goal of improving access to safe and effective medical countermeasures, should the need arise. These efforts are central to strengthening national preparedness and security.

The "Animal Rule" (21 CFR 314.600 for drugs; 21 CFR 601.9 for biological products) permits animal models to be